KRAS and familial pancreatic carcinoma: This was further examined using an autophagy inhibition model achieved through the inducible expression of a dominant-negative Atg4BCA in KRas mutant-driven pancreatic cancer GEM model to co-express Atg4BCA with mutants Kras and Trp53 in all pancreatic cells under the control with doxycycline.